37178-11-3

Basic information

• Product Name: Z-LYS(BOC)-LEU-OME
• Synonyms: (S)-methyl 2-((S)-2-(benzyloxycarbonylamino)-6-(tert-butoxycarbonylamino)hexanamido)-4-methylpentanoate;CBZ-Lys(Boc)-Leu-OMe;Z-LYS(BOC)-LEU-OME
• CAS NO: 37178-11-3
• Molecular Formula: C26H41N3O7
• Molecular Weight: 507.62
• Mol File: 37178-11-3.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• Storage Temp.: -15°C
• CAS DataBase Reference: Z-LYS(BOC)-LEU-OME(CAS DataBase Reference)
• NIST Chemistry Reference: Z-LYS(BOC)-LEU-OME(37178-11-3)
• EPA Substance Registry System: Z-LYS(BOC)-LEU-OME(37178-11-3)

Safety Data

• Hazardous Substances Data: 37178-11-3(Hazardous Substances Data)

Usage

Description

Z-LYS(BOC)-LEU-OME, with the CAS number 37178-11-3, is a boc-protected derivative of L-leucine (L330110) and belongs to the class of N-acyloligopeptides. It possesses antituberculotic properties, making it a potential candidate for the development of new treatments against tuberculosis.

Uses

Used in Pharmaceutical Industry:
Z-LYS(BOC)-LEU-OME is used as a pharmaceutical compound for its antituberculotic properties. It targets the growth and proliferation of Mycobacterium tuberculosis, the bacteria responsible for tuberculosis, by disrupting essential cellular processes and inhibiting the bacteria's ability to survive and multiply.
Additionally, due to its N-acyloligopeptide structure, Z-LYS(BOC)-LEU-OME may also be utilized in the development of other therapeutic agents targeting various diseases and conditions, as it can potentially modulate specific biological pathways and interactions.
Used in Research and Development:
In the field of research and development, Z-LYS(BOC)-LEU-OME serves as a valuable tool for studying the mechanisms of action and potential applications of N-acyloligopeptides. It can be used to investigate the interactions between these compounds and their target proteins or enzymes, as well as to explore the structure-activity relationships of N-acyloligopeptides in various biological contexts.
Furthermore, Z-LYS(BOC)-LEU-OME can be employed in the synthesis of novel N-acyloligopeptides with improved properties, such as enhanced stability, bioavailability, and selectivity, which could lead to the development of more effective therapeutic agents for various diseases.